Morepen Laboratories Gains 4.98%: 5 Key Factors Driving the Week’s Momentum

9 February: Strong Intraday Rally and Valuation Reassessment

Morepen Laboratories Ltd began the week with a robust intraday rally on 9 February 2026, surging 7.33% to reach a high of Rs.39.43. The stock closed at Rs.39.53, up 7.65% from the previous close of Rs.36.72, significantly outperforming the Sensex’s 1.04% gain to 37,113.23. This marked a reversal after two days of decline and was supported by strong buying momentum and a gap-up opening.

Alongside the price surge, the company’s valuation parameters improved, with the price-to-earnings ratio moderating to 26.68 and the valuation grade shifting from fair to attractive. This contrasted with many sector peers trading at higher multiples, positioning Morepen Laboratories as a relatively more appealing option amid ongoing pharmaceutical sector challenges. However, profitability metrics such as ROCE and ROE remained modest at 7.19% and 6.31% respectively, indicating limited operational efficiency despite the valuation appeal.

10 February: Upgrade to Sell Rating Amid Mixed Technical Signals

On 10 February, Morepen Laboratories Ltd’s Mojo Score improved to 31.0, prompting an upgrade in its Mojo Grade from Strong Sell to Sell. This reflected a mild improvement in technical indicators and valuation metrics, despite ongoing financial challenges. The stock closed at Rs.40.02, up 1.24% from the previous day, with intraday highs touching Rs.41.00.

Technical momentum shifted from strongly bearish to mildly bearish, with the MACD remaining bearish but other indicators such as the Dow Theory weekly chart turning mildly bullish. The Relative Strength Index (RSI) showed neutral momentum, while Bollinger Bands suggested subdued volatility with a slight downward bias. Despite the price gains, volume-based indicators like On-Balance Volume (OBV) failed to confirm strong buying interest, signalling caution.

Valuation metrics also adjusted, with the price-to-earnings ratio rising to 28.72 and the valuation grade moving from attractive to fair. Enterprise value multiples remained moderate, supporting the cautious upgrade. However, the company’s financial trend remained weak, with three consecutive quarters of negative results and declining profitability, including a 41.0% drop in profit before tax excluding other income.

11 February: Flat Quarterly Performance Amid Record Sales

Morepen Laboratories reported a flat quarterly performance for the December 2025 quarter, signalling stabilisation after prior declines. Net sales reached a record high of Rs.484.16 crores, with operating profit before depreciation, interest and taxes (PBDIT) at Rs.46.31 crores, yielding an operating margin of 9.57%, the highest in recent periods.

Profit before tax excluding other income also peaked at Rs.31.61 crores, while profit after tax stood at Rs.27.51 crores. Despite these operational improvements, profitability pressures persisted, with a 26.59% decline in PAT over the last six months and a low return on capital employed of 8.16%. Liquidity concerns were evident as cash and cash equivalents fell to Rs.40.28 crores, potentially constraining future investments.

The stock closed at Rs.39.66, down 0.90% from the previous day, reflecting mixed investor reaction to the results. Over shorter time frames, Morepen outperformed the Sensex, but longer-term returns remained subdued.

13 February: Technical Momentum Shifts Bearish Amid Price Decline

On 13 February, Morepen Laboratories experienced a reversal in technical momentum, shifting from mildly bearish to outright bearish. The stock closed at Rs.38.55, down 1.20% from the previous close, while the Sensex declined 1.40% to 36,532.48. Key momentum indicators such as MACD and Know Sure Thing (KST) remained bearish on weekly and monthly charts, confirming sustained selling pressure.

Relative Strength Index (RSI) remained neutral, and Bollinger Bands indicated mild bearishness with contracting volatility. Daily moving averages were firmly bearish, with the stock trading below key short- and medium-term averages. On-Balance Volume (OBV) showed weak volume support, and Dow Theory presented mixed signals with mild weekly bullishness but no monthly trend.

Morepen’s year-to-date and one-year returns lagged the Sensex, underscoring ongoing challenges despite recent technical upgrades. The downgrade in technical momentum suggests increased downside risk in the near term, advising caution for investors.

Daily Price Performance vs Sensex

Key Takeaways

Positive Signals: The stock’s 4.98% weekly gain significantly outperformed the Sensex’s 0.54% decline, driven by strong intraday rallies and a technical upgrade from Strong Sell to Sell. Valuation metrics improved, with the stock trading at more attractive multiples relative to peers. Record quarterly sales and operating margins indicate operational resilience amid sector headwinds.

Cautionary Signals: Despite short-term gains, technical momentum remains fragile with bearish MACD and KST indicators. Profitability pressures persist, with declining PAT and low ROCE. Liquidity constraints and weak volume support temper optimism. The stock’s long-term returns lag the broader market, reflecting structural challenges.

Investor Considerations: The week’s developments suggest a tentative stabilisation phase for Morepen Laboratories, with mixed signals from technical and fundamental perspectives. While valuation attractiveness and recent upgrades offer some encouragement, ongoing financial and momentum risks warrant a cautious approach.

Conclusion

Morepen Laboratories Ltd’s week was characterised by a notable rebound in price and a cautious upgrade in technical and valuation ratings, reflecting a complex interplay of positive momentum and lingering challenges. The stock’s outperformance against the Sensex underscores renewed investor interest, yet persistent bearish technical indicators and mixed financial results highlight the need for vigilance. As the company navigates sector pressures and operational hurdles, its trajectory remains uncertain, with further confirmation required to establish a sustained uptrend. Investors should balance the improved valuation and technical signals against the fundamental risks and market volatility when assessing Morepen Laboratories’ prospects.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →